Koenraad is founder and CEO of Leyden Labs in The Netherlands. Leyden Labs is a biotech company that aims to help people live their lives to the fullest by developing intranasal products that protect against known and future respiratory viruses.
Previous to his current role, Koenraad was a Partner at McKinsey & Company within the Life Sciences practice where he advised pharmaceutical, biotech and medtech companies throughout Europe and the US. Prior to McKinsey, Koenraad worked in business development of a San Francisco based biotech company.
In the competitive landscape of biotech and medical devices, the ability to secure investment hinges on more than just promising science. Top tier U.S. investors like ARCH Venture Partners emphasize that a compelling investment case must clearly articulate the broader impact and commercial potential of the innovation, while also detailing a realistic path to regulatory approval (ARCH Venture Partners).
The session with Koenraad will provide a deep dive into the key elements that make an investment case compelling to top-tier investors in biotech. You will explore how to:
Quantify the market opportunity and align it with a well-defined unmet medical need.
Detail your regulatory and de-risking strategies, ensuring investors see a clear path to market.
Present your technology’s scalability and commercial viability, a crucial aspect always highlighted by investors, who look for innovations that can generate substantial returns.
Showcase the leadership and expertise of your team, which again is identified by many investors as a major determinant of success.